Review





Similar Products

tbk1 ikkε inhibitor bx795  (InvivoGen)
95
InvivoGen tbk1 ikkε inhibitor bx795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Tbk1 Ikkε Inhibitor Bx795, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/pmc13437461-32-19-22
Average 95 stars, based on 1 article reviews
tbk1 ikkε inhibitor bx795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
rig i inhibitor bx795  (MedChemExpress)
95
MedChemExpress rig i inhibitor bx795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Rig I Inhibitor Bx795, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/pm42316185-92-22-29
Average 95 stars, based on 1 article reviews
rig i inhibitor bx795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
bx795  (InvivoGen)
95
InvivoGen bx795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Bx795, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/pm42410595-259-42-48
Average 95 stars, based on 1 article reviews
bx795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
bx 795  (InvivoGen)
95
InvivoGen bx 795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Bx 795, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/pm42358009-40-58-59
Average 95 stars, based on 1 article reviews
bx 795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
tbk1 inhibitor bx795  (InvivoGen)
95
InvivoGen tbk1 inhibitor bx795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Tbk1 Inhibitor Bx795, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/pm42258350-282-4-7
Average 95 stars, based on 1 article reviews
tbk1 inhibitor bx795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
bx 795  (MedChemExpress)
95
MedChemExpress bx 795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Bx 795, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/bio_rxiv__64898__2026__04__21__718880-326-16-17
Average 95 stars, based on 1 article reviews
bx 795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
bx795  (MedChemExpress)
95
MedChemExpress bx795
<t>TLR2/TBK1</t> signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor <t>BX795</t> (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .
Bx795, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bx795/BX795/pm42035609-59-2-8
Average 95 stars, based on 1 article reviews
bx795 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


TLR2/TBK1 signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor BX795 (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .

Journal: Frontiers in Immunology

Article Title: Nuclear IL-33 amplifies NF-κB signaling to drive neutrophil recruitment and activation in the endocervical epithelium during Mycoplasma genitalium infection

doi: 10.3389/fimmu.2026.1820874

Figure Lengend Snippet: TLR2/TBK1 signaling drives IL-33 mRNA expression. (A) IL-33 mRNA expression in cells stimulated with M. genitalium (100 MOI), heat-killed M. genitalium (HK-Mg, equivalent to MOI 100), or purified membrane lipoproteins (LP, 10μg/ml). (B) Cells were pretreated with anti-TLR2 Ab (10μg/ml), C29 (50μmol/L), or TAK-242 (1μmol/L) for 1h prior to infection; IL-33 levels were measured by qPCR. DMSO (0.1%) employed as the vehicle control. (C) Immunoblot of p-TBK1 (Ser172) and total TBK1 kinetics following infection. (D) Cells were treated with the TBK1 inhibitor BX795 (10 μmol/L) and IL-33 mRNA was quantified by qPCR. (E) End1/E6E7 cells were transfected with TBK1 siRNA, and the knockdown efficiency was assessed by qPCR. (F) IL-33 mRNA levels were measured in TBK1−depleted cells by qPCR. (G) Co-IP of TLR2 and TBK1 from cell lysates infected with M. genitalium . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05, **p < 0.01 as compared with the uninfected control (A) or indicated groups (B, D–G) . ns, no significant difference between groups (B, E) .

Article Snippet: Specific pharmacological inhibitors included: the TLR2 inhibitor C29 (MedChemExpress); the TLR4 signaling inhibitor TAK-242 (CLI-095, InvivoGen); and the specific TBK1/IKKε inhibitor BX795 (InvivoGen).

Techniques: Expressing, Purification, Membrane, Infection, Control, Western Blot, Transfection, Knockdown, Co-Immunoprecipitation Assay

IRF1 and IRF7 are transcriptional regulators of IL-33 . (A) Immunoblot of IRF1 and IRF7 in nuclear fractions of cells infected with M. genitalium for 24 h. (B) Impact of TBK1 inhibitor BX795 on the nuclear accumulation of IRF1 and IRF7, DMSO (0.1%) employed as the vehicle control. (C, D) ChIP-qPCR analysis of IRF1 and IRF7 binding to the IL-33 promoter. Data are expressed as the percentage of input DNA (% Input). (E–G) End1/E6E7 cells were transfected with shRNA targeting IRF1 or IRF7, followed by M. genitalium infection. IL-33 mRNA and protein levels were assessed by qPCR (E, F) and immunoblot (G) . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05 vs. indicated groups (C–F) .

Journal: Frontiers in Immunology

Article Title: Nuclear IL-33 amplifies NF-κB signaling to drive neutrophil recruitment and activation in the endocervical epithelium during Mycoplasma genitalium infection

doi: 10.3389/fimmu.2026.1820874

Figure Lengend Snippet: IRF1 and IRF7 are transcriptional regulators of IL-33 . (A) Immunoblot of IRF1 and IRF7 in nuclear fractions of cells infected with M. genitalium for 24 h. (B) Impact of TBK1 inhibitor BX795 on the nuclear accumulation of IRF1 and IRF7, DMSO (0.1%) employed as the vehicle control. (C, D) ChIP-qPCR analysis of IRF1 and IRF7 binding to the IL-33 promoter. Data are expressed as the percentage of input DNA (% Input). (E–G) End1/E6E7 cells were transfected with shRNA targeting IRF1 or IRF7, followed by M. genitalium infection. IL-33 mRNA and protein levels were assessed by qPCR (E, F) and immunoblot (G) . Data are mean ± SEM of three independent biological experiments (n=3). *p < 0.05 vs. indicated groups (C–F) .

Article Snippet: Specific pharmacological inhibitors included: the TLR2 inhibitor C29 (MedChemExpress); the TLR4 signaling inhibitor TAK-242 (CLI-095, InvivoGen); and the specific TBK1/IKKε inhibitor BX795 (InvivoGen).

Techniques: Western Blot, Infection, Control, ChIP-qPCR, Analysis, Binding Assay, Transfection, shRNA, Real-time Polymerase Chain Reaction